Palynziq is used for the treatment of phenylketonuria (PKU) in adults aged 16 and older who have uncontrolled blood phenylalanine levels (above 600 micromol/L) despite being on other PKU management therapies.
In more detail:
Palynziq addresses a critical need for PKU patients who struggle to manage their blood phenylalanine levels with dietary restrictions and other available treatments.
-
Phenylketonuria (PKU): PKU is a rare inherited metabolic disorder that causes a buildup of phenylalanine (Phe) in the body. Phe is an amino acid that is essential for growth and development, but if levels get too high, it can cause neurological problems.
-
Inadequate Blood Phenylalanine Control: Some individuals with PKU find it difficult to maintain safe blood Phe levels even with careful dietary management and other treatments. This can lead to long-term complications. Palynziq is specifically intended for these patients.
-
Age Indication: Palynziq is approved for use in patients aged 16 years and older.
Essentially, Palynziq provides an alternative or supplemental approach to managing PKU in adults when traditional methods are not sufficient.
